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Abstract 20 
A population of neurones in the medial part of the medial preoptic area (mPOA) 21 
transiently express melanin concentrating hormone (MCH) in mid to late lactation in 22 
the rat, and this expression disappears on weaning.  Prolactin is known to mediate 23 
many of the physiological adaptations that occur within the dam associated with 24 
lactation and the mPOA is well endowed with prolactin receptors (Prlr) hence we 25 
hypothesized that these transiently MCH-expressing cells may be regulated by 26 
prolactin.  By in situ hybridization we show that approximately 60 % of the cells 27 
expressing prepro-MCH (Pmch) mRNA in the medial part of the mPOA on Day 19 of 28 
lactation also express Prlr mRNA.  To demonstrate that these transiently MCH-29 
expressing cells can acutely respond to prolactin, , dams were treated with 30 
bromocriptine on the morning of Day 19 of lactation and then given vehicle or 31 
prolactin 4 h later.  In the prolactin-treated animals, over 80 % of the MCH-32 
immunopositive cells were also immunopositive for phosphorylated signal 33 
transducer and activator of transcription 5 (pSTAT5), an indicator of prolactin 34 
receptor activation: double immunopositive cells were rare in vehicle-treated 35 
animals.  Finally, the effect of manipulating the circulating concentrations of 36 
prolactin on Days 17, 18 and 19 on the number of MCH-immunopositive cells on 37 
Day19 was determined.  Reducing circulating concentrations of prolactin over Days 38 
17, 18 and 19 of lactation with or without a suckling stimulus resulted in a reduction 39 
(p < 0.05) in the number of MCH-immunopositive cells in the medial part of the 40 
mPOA on Day 19 of lactation.  Further research is required to determine the 41 
functional role(s) of these prolactin-activated transiently MCH-expressing neurones 42 
however we suggest the most likely role involves adaptations in maternal 43 
metabolism to support the final week of lactation.   44 
285 words  45 
Introduction 46 
Melanin concentrating hormone (MCH) is a neuropeptide predominately expressed 47 
in the incerto-hypothalamus and lateral hypothalamus and has roles in a wide 48 
variety of physiological functions including energy balance and reproduction 49 
(reviewed by both: 1, 2).  Additional expression of prepro-MCH (Pmch) in the medial 50 
part of the medial preoptic area (mPOA) and the paraventricular nucleus (PVN) 51 
during lactation was first described by Knollema and colleagues (3).  In virgin or 52 
pregnant rats, Pmch expression is not detected in these regions (3, 4).  The Pmch/ 53 
MCH-immunopositive cells first appear in the medial part of the mPOA and PVN in 54 
mid-lactation (Days 8-14) in the rat and the highest number have been reported on 55 
Days 15-21 (3, 4).   There is no MCH-immunopositive staining in these cell bodies 56 
after weaning (3).  A decrease in the number of MCH-immunopositive cells within 57 
the mPOA between Days 15 and 21 of lactation independent of the suckling stimulus 58 
has been reported (5).  However others have reported that the number of suckling 59 
pups was positively correlated with the number of MCH-immunopositive cells within 60 
the mPOA on Days 12, 15 and 19 of lactation and that the number of cells increased 61 
as lactation progressed (6).  62 
 63 
The mPOA of the lactating dam is associated with changes in maternal behaviour (7, 64 
8, 9; reviewed by 10, 11, 12, 13).  To date however the emphasis has been on 65 
understanding the role of the mPOA in establishing both maternal behaviours and 66 
maternal physiological responses to the initiation and maintenance of early 67 
lactation.  There is a paucity of research investigating the period of late lactation 68 
even though it is recognised that there are changes in maternal behaviour (14) as 69 
well as changes in both the dam’s food intake and body weight (15) and, if she is not 70 
already pregnant, the activity of her reproductive axis in anticipation of oestrus 71 
following weaning (16).  The function of the cells transiently expressing MCH in the 72 
medial part of the mPOA are unknown but it is not unreasonable to speculate that 73 
they may be involved in one or more of these changes in maternal behaviour and 74 
physiology in late lactation.  The role of prolactin in stimulating the initiation of 75 
maternal behaviours during lactation is well established (reviewed by 10, 13, 17).  76 
The mPOA is a brain region rich in prolactin receptors (Prlr: 13, 18, 19, 20, 21) and 77 
the number of receptors increases with lactation (22, 23).  Prolactin concentrations 78 
remain high through lactation, stimulated by the suckling stimulus (25, 26).  We 79 
therefore hypothesized that the transient expression of MCH in the medial part of 80 
the mPOA in late lactation is regulated by prolactin. 81 
 82 
Whilst transient expression of MCH has been reported in cells in both the mPOA and 83 
the PVN, in the present study we have exclusively investigated the population found 84 
in the medial part of the mPOA.  The first aim of this study, was to determine if Pmch 85 
and Prlr co-express in the mPOA on Day 19 of lactation.  Having demonstrated co-86 
expression, the second aim was to demonstrate if these MCH-immunopositive cells 87 
on Day 19 of lactation would acutely respond to prolactin by expressing 88 
immunoreactive phosphorylated signal transducer and activator of transcription 5 89 
(pSTAT5), an indicator of prolactin receptor activation.  The majority of the MCH-90 
immunopositive cells in the mPOA did acutely respond to prolactin.  Finally, the 91 
effect of reducing circulating concentrations of prolactin in late lactation on the 92 
number of MCH-immunopositive cells within the medial part of the mPOA on Day 19 93 
of lactation was determined.   Two methods of reducing circulating prolactin 94 
concentrations were employed to control for any suckling stimulus effects.  Lactating 95 
rats suckling 8 pups were administered with a dopaminergic agonist, bromocriptine, 96 
to inhibit prolactin release on Days 17, 18 and 19.  The suckling stimulus was 97 
maintained in these animals through continuous cross-fostering.  Another group of 98 
lactating rats suckling 8 pups had their pups removed on Day 17 resulting in both a 99 
decrease in prolactin release and the removal of the suckling stimulus.    100 
 101 
Methods 102 
Animals and experimental treatments 103 
Female Sprague-Dawley rats aged 10 weeks were obtained from the Hercus Taieri 104 
Research Facility at the University of Otago.  Animals were group-housed (n=6 per 105 
cage), unless stated otherwise, and maintained under a 14:10 h light:dark cycle with 106 
an ambient temperature of 22 ± 1°C.  Food and water were available ad libitum 107 
throughout the duration of the experiments.  All experimental procedures were 108 
approved by the University of Otago Animal Ethics Committee. 109 
 110 
To generate lactating rats, the stage of the oestrous cycle was monitored daily by 111 
collection of vaginal smears and on the day of a positive proestrous smear, individual 112 
rats were housed overnight with a male and mating confirmed by the presence of 113 
spermatozoa in the vaginal smear the following morning.  Pregnant females were 114 
individually housed from around day 16 of pregnancy.  On Day 2 postpartum (day of 115 
birth=Day 0 postpartum), litters were normalized to 8 pups each and then circulating 116 
prolactin concentrations were manipulated on Days 17-19 of established lactation as 117 
described next.   118 
 119 
One group of lactating rats (vehicle plus suckling, n=6) received vehicle (250 µl saline 120 
in 10% ethanol) sub-cutaneously at 8 am and 6 pm on Days 17 and 18 of lactation 121 
and at 8 am on Day 19 of lactation.  Pups were cross-fostered every 12 h.  Two hours 122 
following the last vehicle injection, rat dams were deeply anaesthetized with sodium 123 
pentobaritone (300 mg/kg) and transcardially perfused with 50 ml of ice-cold saline 124 
followed by 250 ml of 4 % paraformaldehyde in 0.1M phosphate buffer (pH 7.4).  A 125 
second group of lactating rats (bromocriptine plus suckling, n=6) received 500 µg of 126 
bromocriptine (500 µg/250 µl saline in 10% ethanol) sub-cutaneously at 8 am and 6 127 
pm on Days 17 and 18 of lactation and at 8 am on Day 19 of lactation to suppress 128 
production of endogenous prolactin.   Pups were cross-fostered every 12 h to ensure 129 
pups were fed, enabling maintenance of the suckling-stimulus despite inhibition of 130 
milk synthesis in bromocriptine-treated dams.  No differences in the number of pups 131 
latched to the nipples or the strength of that latching were noted every 12 h when 132 
the pups were removed and replaced from either the vehicle- or bromocriptine-133 
treated dams every 12 h.  In between cross-fostering time points, no behavioural 134 
changes between the pups suckling the bromocriptine-treated dams and those not 135 
treated with bromocriptine were noted.      Rats were perfused 2 h following the final 136 
bromocriptine injection.  A third group of rats (vehicle and no suckling, n=4) received 137 
vehicle injections as above on lactation days 17 and 18 and 19 but on day 17 of 138 
lactation the pups were removed.  Rats were perfused 2 h after the final vehicle 139 
injection on day 19.   140 
 141 
Finally, to examine the acute response to prolactin, a group of lactating rats (n=9) 142 
were injected with bromocriptine at 8 am on day 19 of lactation only as described 143 
above.  Four hours later these same animals were injected intra-peritoneally with 144 
either 1 mg/kg body weight ovine prolactin (n=6; Sigma, St. Louis MO) dissolved in 145 
sterile saline or given vehicle alone (n=3).  Rats were anaesthetised 45 min later and 146 
perfused as described above.  Sections from these rats were processed to determine 147 
the number of MCH-immunopositive cells that were also immunopositive for 148 
pSTAT5. 149 
 150 
Following transcardial perfusion, all brains were removed, post-fixed overnight in 151 
the same fixative solution, then cryoprotected in a 30% sucrose solution in 0.1 M 152 
phosphate buffer till the brains sank.  Brains were then frozen on powdered dry ice 153 
and stored at -80°C until sectioned using a cryostat.  A series of coronal sections 154 
(alternatively, 16 µm thick for in situ hybridization and 30 µm thick for free-floating 155 
immunohistochemistry) were cut through the mPOA from approximately bregma -156 
0.24 mm to bregma -1.32 mm.  An additional series of 16 µm and 30 µm thick 157 
sections were cut at the level of the incerto-hypothalamic and lateral hypothalamic 158 
areas (approximately bregma -1.30 mm to bregma -3.24 mm).  Sections for in situ 159 
hybridization were mounted onto APS-coated slides and stored at -20°C with 160 
dessicant.  Sections for immunohistochemistry were collected into cryoprotectant 161 
solution in 12-well plates and stored at -20°C. 162 
 163 
Double-label in situ hybridization for Pmch and the long form of the prolactin 164 
receptor (Prlr) mRNA 165 
Preliminary single label in situ hybridization experiments comparing the distribution 166 
and abundance of Pmch-mRNA expressing cells detected using isotopically labelled 167 
probes with the distribution detected using non-radioactively labelled probes 168 
(digoxigenin), established that with our protocol digoxigenin-labelled probes were 169 
sufficiently sensitive and specific to label Pmch mRNA in the mPOA. To 170 
simultaneously detect mRNA for both Pmch and the long form of the prolactin 171 
receptor (Prlr) in tissue sections, double-label in situ hybridizations were performed. 172 
Template cDNA was prepared by PCR using primer pairs designed from GenBank 173 
(Bethesda, MD) mRNA sequences for pro-melanin-concentrating hormone (Pmch: 174 
Accession number NM-012625.1, nucleotides 294-527) and the long form of the 175 
prolactin receptor (Prlr: Accession number NM_001034111, nucleotides 1344-1644).  176 
T7 and SP6 promotor sequences were incorporated onto the ends of the primer 177 
sequences and the resulting cDNA templates then used to directly transcribe RNA 178 
hybridization probes.  The specificities of the cDNA templates were confirmed by 179 
Sanger sequencing.   Antisense and sense probes were synthesized using a 180 
digoxigenin RNA-labeling kit for Pmch (Roche Diagnostics GmbH, Mannheim) and 181 
antisense and sense probes labelled with 35S-UTP were generated for Prlr using an in 182 
vitro transcription kit (Promega, Madison, WI).  Unincorporated nucleotides were 183 
removed by running the probes through mini Quick spin RNA columns (Roche 184 
Diagnostics GmbH, Mannheim).  185 
 186 
Sections containing either the mPOA or the incerto-hypothalamic and lateral 187 
hypothalamic areas from lactating animals either treated with bromocriptine or 188 
vehicle on Days 17, 18 and 19 were thawed for 5 min at 55°C, then immersed in 2 % 189 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.4) for 5 min, washed in sodium 190 
citrate buffer (SSC: 150 mM NaCl, 15 mM sodium citrate, pH 7.0), then permeablized 191 
with proteinase K (2 µg/ml) followed by acetylation with 0.1M triethanolamine HCl 192 
(pH 8) containing 0.25% acetic anhydride for 10 min. Following washes with SSC, 193 
sections were subjected to a series of graded alcohol/chloroform steps, before being 194 
air-dried for 2-3 h.  A total volume of 90 µl hybridization buffer (100 mM DDT, 0.3 M 195 
NaCl, 20 mM Tris pH 8, 5 mM EDTA, 1 X Denhardt’s solution, 10 % dextran sulphate, 196 
50 % formamide) containing 25 ng of digoxigenin-labeled Pmch antisense or sense 197 
probe/100 µl of hybridization buffer and approximately 833,300 cpm of 35S-labelled 198 
Prlr antisense or sense probes/100 µl of hybridization buffer were applied to each 199 
slide and the slides coverslipped with Hybrislips.   200 
 201 
Hybridizations were carried out overnight at 55C then slides were washed with SCC 202 
buffer (all post-hybridization SSC washes also had 10 mM B-mercaptoethanol and 1 203 
mM EDTA added to the solution) and treated with Ribonuclease A (20 µg/l) for 30 204 
min at room. Following additional SSC washes (most stringent wash, 0.1 X SSC at 64 205 
C for 2 h), sections were washed in a solution of 100 mM Tris/150mM NaCl (pH 7.5) 206 
and then incubated for 48 h with anti-digoxigenin antibody conjugated to alkaline 207 
phosphatase (diluted 1:2000).  Sections were washed 3 times, then incubated in 208 
levamisole (1 mg/ml) solution. The digoxigenin-labeled probes were detected by 209 
incubation with NBT/BCIP (nitroblue tetrazolium chloride/5-bromo-4 chloro-3-210 
indolyl-phosphate) substrate for 24 h followed by four, consecutive 30 min washes in 211 
buffer (150 mM NaCl, 10 mM NaH2PO4, 1 mM EDTA) to eliminate residual NBT and 212 
BCIP.  Sections were then dipped briefly in distilled water followed by 70% ethanol 213 
and dried at RT.  Slides were exposed to scientific imaging film for 7 days to generate 214 
autoradiograms and subsequently coated with LM-1 Hypercoat emulsion (Amersham 215 
Biosciences), placed in light-proof slide boxes containing desiccant and stored at 4C 216 
for 5 weeks.  Slides were developed in Kodak D19, fixed with Ilford Hypan, 217 
dehydrated through graded ethanols and cleared in xylene before coverslipping with 218 
VectaMount mounting medium. 219 
 220 
Double-label immunohistochemistry for MCH and pSTAT5 221 
Sections taken from the mPOA and the incerto-hypothalamic and lateral 222 
hypothalamic areas of the lactating animals given bromocriptine and prolactin or 223 
vehicle on Day 19 only were dual-labelled for MCH and pSTAT5.  Sections were 224 
treated as for single-label immunohistochemistry (described below) with the 225 
addition of an antigen-retrieval step (for pSTAT5: 27): sections were incubated with 226 
0.01M Tris (pH10) for 10 min at 90°C immediately following 6 x washes in 0.05M TBS  227 
to remove cryoprotectant. Sections were then incubated in blocking solution (0.05 M 228 
TBS, 0.25% Triton-X-100, 2 % BSA) for 1 h and endogenous peroxidases quenched in 229 
a 1% hydrogen peroxide/ 40% methanol solution for 10 min. After 3 x 10 min washes 230 
the tissue was incubated for 48 h at 4 °C in blocking solution containing 1.5% normal 231 
goat serum and rabbit anti-pSTAT5 (Tyr694, Cell Signalling Technology, Beverly, MA; 232 
RRID:AB_2315225) at a 1:2,000 dilution. After further rinses, and incubation in 233 
biotinylated secondary goat anti-rabbit antibody (Vector, BA-1000; 234 
RRID:AB_2313606) diluted 1:500 for 90 min at RT, sections were incubated for 1 h at 235 
RT in avidin-biotin-complex solution (ABC Elite kit; Vector Laboratories, Burlingame, 236 
CA, USA). Staining for pSTAT5 was then visualized using nickel-enhanced 3-3’-237 
diaminobenzidine solution catalyzed with glucose oxidase to produce black nuclear 238 
staining.  This step was followed by a second peroxidase activity quenching step 239 
before incubating tissue in blocking solution containing 1.5% normal goat serum and 240 
anti-MCH (M8440, Sigma-Aldrich; RRID:AB_260690) diluted 1:80,000 for 24-48 h at 241 
4°C.  After a TBS wash, sections were incubated with secondary antibody horseradish 242 
peroxidase-conjugated goat anti-rabbit IgG (DAKO) at 1:400 dilution for 90 min.  243 
Sections were then reacted with non-nickel-enhanced 3-3’-diaminobenzidine 244 
solution resulting in brown cytoplasmic staining of MCH-immunopositive cells. 245 
Sections were mounted onto slides and processed as for single label 246 
immunohistochemistry (below).  In addition, each run included negative control 247 
sections in which the primary antibody was omitted from the wells. No staining was 248 
observed in these sections. 249 
 250 
Single-label immunohistochemistry for MCH 251 
To identify the number of MCH-immunopositive cells in the mPOA following 252 
manipulation of prolactin release, free-floating sections containing either the mPOA 253 
or the incerto-hypothalamic and lateral hypothalamic area were washed 6 x in 0.05 254 
M TBS (50 mM Tris, 150 mM NaCl, pH 7.6) to remove cryoprotectant, followed by 255 
incubation in blocking solution (0.05 M TBS, 0.25% Triton-X-100, 2 % BSA) for 1 h.  256 
Endogenous peroxidases were quenched in a 1% hydrogen peroxide/ 40% methanol 257 
solution for 10 mins, washed again then incubated for 48 h at 4°C in blocking 258 
solution containing 1.5% normal goat serum and anti-MCH (M8440, Sigma-Aldrich; 259 
RRID:AB_260690) at a 1:80,000 dilution. Following further washes in 0.05M TBS, the 260 
tissue was incubated for 2-3 h with biotinylated secondary goat anti-rabbit antibody 261 
diluted 1:500. Next, sections were incubated with avidin-biotin-complex (ABC Elite 262 
kit; Vector Laboratories, Burlingame, CA, USA) for 1 h at RT. Finally, MCH 263 
immunoreactively was visualized by incubation in nickel-enhanced 3-3’-264 
diaminobenzidine solution catalyzed with glucose oxidase to produce black 265 
cytoplasmic staining.  Sections were then mounted onto gelatin-coated slides, dried 266 
overnight before dehydration in a series of graded alcohols, cleared in xylene and 267 
coverslipped under DPX-mounting medium. 268 
 269 
Analyses 270 
The total number of Pmch mRNA-expressing cells and the number of Pmch mRNA-271 
expressing cells that co-expressed Prlr mRNA within the mPOA on both sides of the 272 
third ventricle were analysed in two sections per animal (n=4 vehicle-treated 273 
animals; n=4 bromocriptine-treated animals). Sections were photographed under 274 
brightfield illumination at 400 x magnification. Pmch mRNA-expressing cells were 275 
identified by the presence of purple/red cytoplasmic staining. To identify double-276 
labelled cells, the number of silver grains (representing Prlr mRNA) overlying each 277 
Pmch mRNA-expressing cell within the mPOA, was quantified using the particle 278 
counting function of ImageJ software. For each section, five background 279 
measurements of silver grain densities also were made over adjacent areas of the 280 
section.  Cells were considered positively labeled for Prlr mRNA if the signal to 281 
background ratio was greater than 3 times mean background values. In sections of 282 
the incerto-hypothalamic and lateral hypothalamic areas, no cells were double-283 
labelled for Pmch mRNA and Prlr mRNA, therefore, cell numbers were not quantified 284 
in these areas. 285 
 286 
For the analysis of co-localization of MCH-immunopositive cells activated by pSTAT5, 287 
digital images were captured under brightfield at 200 X magnification using an 288 
Olympus AX70 microscope and QImaging Micropublisher digital camera.  The total 289 
number of MCH-immunopositive cells and the total number of MCH-immunopositive 290 
cells displaying clear nuclear pSTAT5 staining were counted in 3 sections 291 
(systematically selected since the anatomical distribution of the MCH-292 
immunopositive cells is very consistent and first cells appear at the same rostro-293 
caudal level) of the mPOA per animal (n=6 prolactin-treated animals; n=3 vehicle-294 
treated animals). The region of the mPOA was outlined and the area overlaid with a 295 
grid using ImageJ. The number of single-labelled and double-labelled cells within 296 
each square of the grid that fell within the area of the mPOA were then identified, 297 
cateogorized and counted.  Only cells that clearly contained brown cytoplasm (MCH-298 
positive cells), or both brown cytoplasmic staining and a distinct black nucleus 299 
(double-labelled cells) were counted.  Only the brightness and contrast of the images 300 
were adjusted. As there was no evidence of double-labelled MCH- and pSTAT5- 301 
immunopositive cells in the incerto-hypothalamic and lateral hypothalamic areas 302 
sections, cell numbers were not quantified in these sections. Data are presented as 303 
the mean percentage of double labelled cells of all the MCH-immunopositive cells 304 
per rat. Experimental differences were analysed by Student’s t-test. 305 
 306 
For the analysis of the single-label immmunohistochemistry, sections were imaged 307 
as for dual-label immunohistochemistry. The total number of MCH-immunopositive 308 
cells present within the boundaries of the mPOA on both sides of the third ventricle 309 
of 3-4 sections per animal were counted. Data are presented as mean number of 310 
immunopositive cells counted per rat ± SEM.  Differences between groups were 311 
analysed by one way analysis of variance followed by Tukey-Kramer post-hoc 312 
analysis. 313 
 314 
All analyses were performed using GraphPad Prism Software and differences 315 
between groups were considered significant if p < 0.05. 316 
 317 
Results 318 
Prepro-MCH (Pmch) mRNA was detected in cells within the medial part of the mPOA, 319 
as well as in a few cells located more medially to these within the periventricular 320 
nucleus, of the hypothalamus of the rat dam on day 19 of lactation (Figure 1a).  321 
Double-label in situ hybridization for both Pmch and Prlr mRNA demonstrated co-322 
localization of the two transcripts in some but not all Pmch mRNA-positive cells 323 
(Figure 1b).  When rats were administered with a dopaminergic agonist, 324 
bromocriptine, on Days 17, 18 and 19, the number of Pmch mRNA-positive cells on 325 
Day 19 was markedly decreased compared to vehicle-treated animals (Figure 1c; p < 326 
0.05).  In both vehicle- and bromocriptine–treated animals, although the total 327 
number of positive cells was different, the proportion of Pmch mRNA positive cells 328 
co-labelled with Prlr mRNA was similar (Figure 1d: 61% of vehicle-treated group 329 
versus 60% of bromocriptine-treated group).  Within the medial mPOA, there were 330 
also many cells that were Prlr mRNA-positive but negative for Pmch mRNA: it was 331 
however not possible to robustly quantify these cells.  Many cells in sections 332 
containing the incerto-hypothalamic and lateral hypothalamic areas strongly 333 
expressed mRNA for Pmch but no co-expression with Prlr mRNA was observed (see 334 
Figure 1e).  No positive labelling was detected in negative control sections incubated 335 
with sense probes (data not shown). 336 
 337 
To determine if the MCH-immunopositive cells found in the mPOA on Day 19 of 338 
lactation were acutely responsive to prolactin, a group of lactating rats were treated 339 
with bromocriptine on the morning of Day 19 only.  Four hours later these rats 340 
received either prolactin or vehicle and 45 min later were killed.  By dual-label 341 
immunohistochemistry, sections from these animals were stained for both MCH 342 
(DAB: brown cytoplasmic staining) and pSTAT5 (nickel-enhanced DAB: black nuclear 343 
staining).  Within the medial part of the mPOA, cells were identified that were either 344 
MCH-immunopositive, both MCH and pSTAT5 immunopositive as well as pSTAT5 345 
immunopositive alone (Figure 2a, b and c).  Of all the MCH-immunopositive cells, the 346 
majority (87.3 %) were also immunopositive for pSTAT5 after the animals were 347 
treated with prolactin (Figure 2d).  When animals were treated with vehicle, the 348 
identification of both MCH- and pSTAT5-immunopositive cells was low because of 349 
their rarity within the mPOA (Figure 2d).  Within the incerto-hypothalamic and the 350 
lateral hypothalamic areas, no cells were identified that were both MCH- and 351 
pSTAT5-immunopositive (Figure 2e and f). 352 
 353 
MCH-immunopositive cells were found in the mPOA on Day 19 of lactation (Figure 354 
3a) and the distribution of the immunopositive cells was very similar to that of cells 355 
expressing Pmch (Figure 1a).  Immunopositive staining for MCH was confined to the 356 
cytoplasm of cells (Figure 3a).  In the absence of prolactin, induced either by 357 
administering bromocriptine on Days 17, 18 and 19 or by withdrawing pups on Day 358 
17, the number of immunopositive cells was markedly reduced on Day 19 (Figure 3b, 359 
c and d: 1 way ANOVA, p < 0.05).  360 
 361 
Discussion 362 
By both in situ hybridization and immunohistochemistry, we have confirmed the 363 
induction of MCH expression in a specific population of cells within the medial part 364 
of the mPOA in established lactation.  For the first time we have demonstrated that 365 
the majority of these MCH-positive cells also express the long form of the prolactin 366 
receptor, and are prolactin responsive during lactation, as indicated by prolactin-367 
induced expression of pSTAT5.  Finally, we have shown that suppression of prolactin 368 
secretion during established lactation markedly reduced expression of MCH, even in 369 
the presence of the ongoing suckling stimulus.  These data demonstrate that 370 
expression of MCH in the medial part of the mPOA during lactation is dependent on 371 
prolactin action. 372 
 373 
As others before, we have confirmed that some cells within the medial part of the 374 
mPOA express Pmch/MCH on day 19 of lactation (3, 4, 5, 6).  We hypothesized that 375 
this transient expression of MCH in the mPOA in late lactation is regulated by 376 
prolactin.  To exert its biological effects, prolactin binds to the long form of the 377 
prolactin receptor (Prlr).   Expression of the long form of the receptor has been 378 
previously demonstrated in the mPOA of both pregnant and early lactating rats (18, 379 
22, 28).  Using double in situ hybridization, we have now demonstrated that the long 380 
form of the Prlr is also expressed in the mPOA of the late lactating rat and that a sub-381 
population of these Prlr mRNA-positive cells also express Pmch.  382 
 383 
When prolactin binds to the long form of the Prlr the JAK/STAT intracellular 384 
signalling pathway is activated and as a result STAT5 is phosphorylated.  385 
Phosphorylated STAT5 (pSTAT5) acts a transcription factor to elicit the biological 386 
effects of prolactin (29).  The detection of immunopositive pSTAT5 is used as a 387 
surrogate marker of the long form of the Prlr because the available antibodies to the 388 
long form of the Prlr are often not sensitive enough (30).  Low numbers of cells 389 
immunopositive for pSTAT5 have previously been detected in the mPOA of virgin 390 
mice with the number increasing in both pregnant and early lactating mice (27, 31).  391 
We have now demonstrated that a significant proportion of the immunopositive 392 
MCH cells found in the mPOA are also immunopositive for pSTAT5 in response to 393 
prolactin administration, but not vehicle, four hours after treatment with 394 
bromocriptine on the morning of Day 19 of lactation only.  Hence, in late lactation a 395 
high proportion of the transiently-expressing MCH cells in the mPOA are being 396 
activated by prolactin.   397 
 398 
The pattern and number of Pmch/ MCH-immunopositive cells has been studied 399 
during lactation in both the incerto-hypothalamus and lateral hypothalamic areas, by 400 
several groups, but usually as a single entity rather than as two distinct areas.  It has 401 
been reported as being decreased (32), unchanged (3, 4, 5) or increased by lactation 402 
(33).  In our study we noted no alteration in pattern of MCH-immunopositive cells in 403 
the incerto-hypothalamus and found no MCH-immunopositive cells co-localized with 404 
pSTAT5 suggesting that prolactin had not acted on any of these cells. 405 
 406 
Expression of MCH in  cells within the medial part of the mPOA in late lactation 407 
requires prolactin, but not suckling per se, and we have demonstrated this in two 408 
ways.  On Day 19 of lactation, the number of MCH-immunopositive cells was 409 
reduced after prolactin release was inhibited either by treatment with bromocriptine 410 
on Days 17, 18 and 19 or pup withdrawal on Day 17 compared with the vehicle 411 
treated controls; that is, with or without the maintenance of a suckling stimulus, 412 
respectively.  We have demonstrated that these MCH-immunopositive cells are also 413 
pSTAT5 immunopositive and hence prolactin activated.  Others have demonstrated 414 
that the number of suckling pups in late lactation determines the number of cell 415 
bodies within the medial part of the mPOA expressing MCH (6).  This would suggest 416 
that neuronal stimulation may stimulate transient MCH expression however it is 417 
likely that this is an indirect effect.  Alvisi and colleagues (5) found no co-localization 418 
of suckling-induced c-Fos expression with MCH in the medial part of the mPOA on 419 
days 15 to 21 of lactation and central administration of prolactin does not induce c-420 
Fos expression in the mPOA of rats (24).  There were still some cells in the mPOA 421 
transiently expressing MCH after the bromocriptine treatment or pup withdrawal 422 
suggesting that either a yet to be identified factor is also involved in their 423 
maintenance or that the time period of the withdrawal of maintenance was 424 
insufficient to extinguish all expression.  Based on our data it would appear therefore 425 
that the suckling stimulus per se is not maintaining the expression of the MCH but 426 
rather that it is the suckling-induced release of prolactin that is responsible (25).   427 
 428 
Although we have demonstrated that prolactin is involved in the maintenance of 429 
these transiently expressing MCH cells within the mPOA in late lactation, it is unlikely 430 
that prolactin initiates this transient expression.  Others have reported that the 431 
transiently expressing MCH cell bodies first appear on Days 8 to 12 of lactation (3, 4).  432 
At this time circulating concentrations of prolactin, albeit not as high as in the early 433 
days of lactation, are still very high compared to a non-lactating female (26).  It is 434 
possible that progesterone may be the primary initiating signal.  The secretion of 435 
progesterone from the corpora lutea of lactation has reached a maximum by Day 8 436 
and started to decline at Day 12 (35).  There are progesterone receptors in the 437 
mPOA at this time: one group reports that the number of oestrogen-induced 438 
progesterone receptors in the mPOA appear to increase in response to increased 439 
circulating oestrogen concentrations in late lactation (day 15 compared to day 20 440 
post-partum) (36) whilst another reports that the number of progesterone receptors 441 
in the mPOA appears to have stabilized at pre-pregnancy numbers by Day 7 of 442 
lactation (34).  Progesterone induces changes in maternal behaviour in the second 443 
half of lactation (34) and these effects may be mediated by the transiently 444 
expressing MCH cells since administration of MCH into the mPOA in early lactation 445 
suppresses maternal behaviours (48).  Another possible trigger may be the mid-446 
lactation decrease in circulating leptin concentrations (37, 38, 39; reviewed by 40).  447 
Leptin receptors have been detected in the mPOA of female non-pregnant, non-448 
lactating mice and rats (41, 42).  In the ob/ob mouse, MCH expression within the 449 
incerto-hypothalamic and lateral hypothalamic areas is increased (43) hence the 450 
mid-lactation nadir in leptin may be responsible for up-regulating MCH expression in 451 
the medial part of the mPOA and then prolactin maintains expression.  It is also 452 
possible that another as yet unidentified trigger could be responsible for initiating 453 
the transient expression of MCH in these cells within the mPOA hence further 454 
research is required. 455 
 456 
The role of the MCH-expressing cells within the medial part of the mPOA remains 457 
uncertain, and we have not directly addressed this in the present study. As they are 458 
maintained by prolactin, then it can be assumed that they are mediating some of the 459 
known roles of prolactin in late lactation.   In late lactation, the possible roles for the 460 
transient prolactin-induced expression of MCH in the mPOA fall broadly into three 461 
areas: adaptive reduction of maternal behaviour preceding weaning; regulation of 462 
the dam’s return to reproductive activity; and modulation of maternal energy 463 
homeostasis.  464 
 465 
A role for MCH in stimulating maternal behaviours (nest building, pup retrieval and 466 
maternal aggression) in early lactation has been suggested (44, 45), but such effects 467 
precede the transient expression of MCH in the medial part of the mPOA and are 468 
likely to involve incerto-hypothalamic MCH neurones.  In late lactation, the dam’s 469 
behaviour to her pups changes as she begins to encourage their increasing 470 
independence as weaning approaches.  These changes in behaviour include a 471 
reduction in pup retrieving and nest building (14) as well as a reduction in the dam’s 472 
aggression in response to intrusion by strange male conspecifics (46, 47).  In contrast 473 
to the stimulatory actions of incerto-hypothalamic MCH neurones, MCH 474 
administration into the mPOA of dams inhibits the normal pup retrieval and nest 475 
building behaviours of early lactation, hence mimicking the behaviours seen in late 476 
lactation (48). Prolactin is thought to be involved in the onset of maternal behavior 477 
at birth, but is not required for ongoing expression of maternal behaviour.  Whether 478 
there is an active role for prolactin, through its action on the transient MCH-479 
expressing cells of the medial mPOA, in termination of maternal behavior during late 480 
lactation has not been evaluated. 481 
 482 
It has long been proposed that in late lactation, lactational anoestrus is primarily 483 
maintained by prolactin (49).  The mPOA is a site of kisspeptin and GnRH cell bodies 484 
that are known to be activated as part of the LH surge (50, 51, 52).  Bilateral 485 
administration of MCH into the mPOA of ovariectomized, oestradiol benzoate-486 
primed rats results in the generation of LH surge-like release of LH (53, 54, 55).  It is 487 
therefore possible that the transiently expressing MCH cells are involved in 488 
stimulating the LH surge that occurs on Day 20 post-partum in the absence of post-489 
partum mating and in the presence of lactation (16).  As for the maternal behaviour 490 
effect, it is difficult though to conceive a role for prolactin in the regulation of the 491 
dam’s return to reproductive activity given the well established inhibitory effects of 492 
prolactin on the hypothalamic-pituitary-gonadal axis.  Recent data suggests that the 493 
inhibitory actions of hyperprolactinemia on the hypothalamic-pituitary-gonadal axis 494 
are exerted through the kisspeptin neurones of the arcuate (56) and therefore 495 
further work is required to understand prolactin’s role(s) in other hypothalamic 496 
areas. 497 
 498 
Both incerto-hypothalamic and lateral hypothalamic MCH play a significant role in 499 
stimulating food intake (43) and MCH expression in these areas are increased by 500 
fasting (57).  It is possible that increased MCH in the mPOA during lactation could 501 
contribute to this orexigenic role. Towards the end of the lactation although the 502 
animals are not fasting, per se, they are in a state of negative energy balance as they 503 
utilize body reserves to maintain milk production.  During the second half of 504 
lactation food consumption is higher (15, 58) and this appears to be regulated by 505 
prolactin, as bromocriptine treatment will reduce food intake while bromocriptine 506 
plus chronic intraventricular infusion of prolactin will restore food consumption to 507 
control amounts (59). The prolactin-activated MCH cell bodies in the medial part of 508 
the mPOA may have a role in increasing food intake.  As suggested by Rondini and 509 
colleagues, it is also possible that other neuropeptides related to metabolic control 510 
and/or leptin may be responsible for the increased expression of MCH in the mPOA 511 
(4); that is, that the role of these transiently expressing MCH, prolactin activated 512 
cells in the face of the “increased energy drain” of late lactation is to stimulate 513 
feeding above the already increased levels seen earlier in lactation.  Further research 514 
is required to determine if these transiently expressing MCH cell bodies have 515 
projections that extend to the third ventricle and participate in the recently 516 
described stimulation of feeding behaviour by MCH through cerebral ventricular 517 
volume transmission (60). 518 
  519 
We have demonstrated that the majority of MCH-immunopositive cells that are 520 
transiently expressed in the medial part of the mPOA during late lactation express 521 
the prolactin receptor and that the maintenance of MCH expression in these cells is 522 
dependent on prolactin action.  Further research is required to determine the 523 
functional role(s) of these prolactin-activated transiently MCH-expressing cells 524 
however the most likely role would appear to involve adaptations in maternal 525 
metabolism to support the final week of lactation.   526 
 527 
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Figure Legends 533 
Figure 1. In situ hybridization showing expression of Pmch mRNA and Prlr mRNA 534 
expressing neurones in sections from a rat dam treated with vehicle (on Days 17, 18 535 
and 19) and suckling pups on Day 19 of lactation (panels a, b and f) and a rat dam 536 
treated with bromocriptine (on Days 17, 18 and 19) and suckling pups on Day 19 of 537 
lactation (panel c): a. Low power dark-field photomicrograph showing the 538 
distribution of Pmch mRNA (white clusters of silver grains) in the mPOA; b. 539 
representative brightfield image of Pmch mRNA-expressing cells (purple/red 540 
cytoplasmic labeling) dual-labeled for prolactin receptor (Prlr) mRNA (black clusters 541 
of silver grains over cells).  Top insert shows a high power image of the area outlined 542 
in the black box of a cell expressing Pmch mRNA only.  Bottom insert shows a high 543 
power image of the area outlined in the black box of two positive dual–labelled cells; 544 
c. representative brightfield image of Pmch mRNA-expressing cells (purple/red 545 
cytoplasmic labeling) dual-labeled for prolactin receptor (Prlr) mRNA (black clusters 546 
of silver grains over cells).  Insert shows a high power image of the area outlined in 547 
the black box of a positive dual–labelled cell; d. quantification of the mean (± SEM) 548 
total number of Pmch mRNA-expressing cells per rat in the mPOA of rat dams 549 
suckling pups on day 19 of lactation after receiving either vehicle (n=4 animals) or 550 
bromocriptine treatment (n=4 animals). *p < 0.05; e. The proportion of Pmch-551 
expressing neurones co-expressing Prlr mRNA in the mPOA on day 19 of lactation 552 
following vehicle or bromocriptine treatment; f. representative low power image of 553 
Pmch mRNA-expressing cells (purple/red cytoplasmic labeling) dual labelled for Prlr 554 
mRNA in the incerto-hypothalamic and lateral hypothalamic areas. In these regions, 555 
no Pmch mRNA-expressing cells were observed to co-express Prlr mRNA. A high 556 
power image of two single-labelled Pmch mRNA-expressing cells is shown in the 557 
insert in e.  Abbreviations, f, fornix; mPOA, medial preoptic area; och, optic chiasm; 558 
3V, third ventricle. Scale bars: (a) = 150 µm; (b and c) = 50 µm, inserts in (b and c) = 559 
10 µm; (e) = 100 µm, insert in (e) = 10 µm.  560 
Figure 2.  Double label immunohistochemistry for melanin concentrating hormone 561 
(MCH: brown cytoplasmic staining) and phosphorylated Stat5 (pStat5: black nuclear 562 
staining) following prolactin administration, in the medial preoptic area (mPOA) of 563 
dams on Day 19 of lactation:  a. representative image of the mPOA (scale bar: 50 564 
µm); b. and c. higher magnification of the boxed areas in (a) with examples of cells 565 
either immuno-positive for MCH (blue arrow) or pSTAT5 alone (orange arrow) or 566 
immuno-positive for both MCH and pSTAT5 (black arrow) (scale bar: 15 µm); d. 567 
quantification of the percentage (± SEM) of cell bodies in the mPOA that were co-568 
labelled for MCH and pSTAT5 following administration of either prolactin or vehicle.  569 
*p < 0.05; e. and f. representative images of (e) low and (f) high, magnification of the 570 
lateral hypothalamus of a rat dam on Day 19 of lactation following prolactin 571 
administration showing MCH immuno-labelling (brown cytoplasmic staining).  No 572 
MCH-immunopositive cell bodies are also immunopositive for pSTAT5.  Arrows 573 
indicate neurones single-labelled for MCH. Scale bars: (e) = 100 µm and (f) = 30 µm. 574 
Abbreviations, f, fornix; ic, internal capsule. 575 
 576 
Figure 3.  Representative images of cell bodies immuno-positive for melanin 577 
concentrating hormone (MCH) in the medial preoptic area of the rat dam on Day 19 578 
of lactation in animals either with circulating concentrations of prolactin 579 
characteristic of lactation (vehicle) or treated to suppress prolactin release 580 
(bromocriptine or pup removal) on Days 17, 18 and 19 of lactation.  a. Vehicle was 581 
administered on Days 17, 18 and 19 of lactation: insert shows examples of cells of 582 
interest at 600 fold magnification (indicated by black arrows); b. bromocriptine was 583 
administered on the mornings of Days 17, 18 and 19 of lactation; and c. pups were 584 
removed on the morning of Day 17 and then the dam received vehicle on Days 17, 585 
18 and 19 of lactation.  All animals were perfused on the afternoon of Day 19 and 586 
the brains prepared for immunohistochemistry.  All low power images taken at 40 x 587 
magnification.  Scale bars: (a-c) = 500 µm insert and insert in (a) = 5 µm. mPOA, 588 
medial preoptic area; och, optic chiasm; 3v, third ventricle.  d. Quantification of the 589 
number of cell bodies immuno-positive for MCH in the medial preoptic area (mPOA) 590 
of the rat dam on Day 19 of lactation in animals either with circulating 591 
concentrations of prolactin characteristic of lactation (a. vehicle, n = 6) or treated to 592 
suppress prolactin release (b. bromocriptine, n = 6 or c. pup removal, n = 4) on Days 593 
17, 18 and 19 of lactation.  Data are presented as the mean ± SEM.  Differences 594 
between means were analysed by one-way ANOVA followed by Turkey-Kramer test, 595 
(F2,13 = 18.98): vehicle versus prolactin withdrawal.  Bars with different letters are 596 
significantly different (p < 0.05). 597 
  598 
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